Cost regulators for the NHS in England and Wales have ruled that Celgene’s Revlimid (lenalidomide) is not a cost-effective option for treating certain patients with multiple myeloma. The National Institute for Health and Care Excellence (NICE) has published draft guidance this morning rejecting Revlimid for people whose disease has relapsed once after receiving one treatment with Janssen Cilag’s Velcade (bortezomib), and are unable to receive thalidomide and for whom bone marrow transplantation is not appropriate. This is because, from the information provided, it is unclear whether Revlimid is as effective as re-treatment with bortezomib, and the manufacturer’s own economic model showed that it would not be cost effective at this stage, the Institute said, explaining the decision.
Help employers find you! Check out all the jobs and post your resume.
